Clinical trial
A Phase 1/2 Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-863233 in Subjects With Advanced and/or Metastatic Solid Tumors
NCT00886782 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2 Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-863233 in Subjects With Advanced and/or Metastatic Solid Tumors
- Lead sponsor
- Bristol-Myers Squibb
- Phase
- Phase 1/2
- Overall status
- Terminated
- Start date
- May 31, 2009
- Completion date
- August 4, 2010
- Enrollment
- 11 (actual)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.
advanced solid cancers, metastatic cancer